Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3016859 in Diabetic Nephropathy
NCT01774981Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2013
- Primary completion
- Aug 2015
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of Fepixnebart in diabetic nephropathy (DN), sponsored by Eli Lilly and Company. Started Mar 2013; status: completed.
02
Drugs
Fepixnebart
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT01774981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01774981.